- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03996226
A Food-Effect Study of E7386 in Healthy Participants
November 13, 2019 updated by: Eisai Inc.
A Phase 1 Food-Effect Study of E7386 in Healthy Subjects
The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of E7386 following single dose administration with and without a meal.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-smoking, healthy participants at the time of informed consent.
- Body Mass Index (BMI) greater than (>) 18 and less than or equal to (<=) 30 kilogram per square meter (kg/m^2) at Screening.
Exclusion Criteria:
- Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per litre (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
Females of childbearing potential who:
Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
- total abstinence (if it is their preferred and usual lifestyle)
- an intrauterine device or intrauterine hormone-releasing system
- a contraceptive implant
- an oral contraceptive (with additional barrier method) (Participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation)
- have a vasectomized partner with confirmed azoospermia
- Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
- Males who have not had a successful vasectomy (confirmed azoospermia) and their female partners meet the exclusion criteria No: 2, above. If the female partner is pregnant, then males who do not agree to use Barrier contraception (latex or synthetic condoms) throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation
- Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
- Any history of major surgery, e.g., intestinal resections, hepatectomy, nephrectomy, digestive organ resection that may affect absorption, metabolism or excretion of E7386.
- Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening
- Clinically significant ECG abnormality including a marked baseline prolongation of QT/corrected QT interval (QTc) (example: repeated demonstration of a QTc interval greater than (>) 500 milliseconds [msec]), or a family history of prolonged QTc syndrome or sudden death
- History of drug or alcohol misuse within 6 months prior to Screening, or who had a positive urine drug test at Screening or Baseline
- Diagnosed with acquired immune deficiency syndrome, or test positive for human immunodeficiency virus (HIV) at screening
- Active viral hepatitis (A, B or C) as demonstrated by positive serology at Screening
- Use of prescription drugs within 4 weeks prior to dosing
- Intake of over-the-counter medications within 2 weeks prior to dosing
- Intake of caffeinated beverages or food within 72 hours prior to dosing
- Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
- Participated in another clinical trial less than 4 weeks prior to dosing or was currently enrolled in another clinical trial
- Consumed grapefruit, starfruit, Seville oranges or their products within 7 days prior to dosing
- Consumed herbal preparations/medications including but not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng within 7 days prior to dosing
- Allergic to E7386 or any of the tablet's ingredients
- Known history of clinically significant drug or food allergies, or presently experiencing significant seasonal or perennial allergy at Screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E7386: Fed + Fast
Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
|
E7386 oral tablets.
|
Experimental: E7386: Fast + Fed
Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
|
E7386 oral tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration for E7386
Time Frame: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for E7386
Time Frame: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
AUC0-t: AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386
Time Frame: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
AUC0-inf: Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for E7386
Time Frame: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 7, 2019
Primary Completion (Actual)
October 29, 2019
Study Completion (Actual)
October 29, 2019
Study Registration Dates
First Submitted
June 21, 2019
First Submitted That Met QC Criteria
June 21, 2019
First Posted (Actual)
June 24, 2019
Study Record Updates
Last Update Posted (Actual)
November 14, 2019
Last Update Submitted That Met QC Criteria
November 13, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- E7386-A001-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Effect in Healthy Participants
-
Jacobio Pharmaceuticals Co., Ltd.Completed
-
ORIC PharmaceuticalsCompleted
-
Pyramid BiosciencesCompletedFood Effect in Healthy VolunteersUnited States
-
Pyramid BiosciencesCompletedFormulation Bridging and Food Effect in Healthy VolunteersUnited States
-
Hutchison Medipharma LimitedCompletedFood Effect of Fruquintinib in Health SubjectsChina
-
AVEO Pharmaceuticals, Inc.CompletedFood Effect of Tivozanib in Health SubjectsUnited States
-
Balance TherapeuticsCompletedHealthy | Food EffectUnited Kingdom
-
Astellas Pharma Global Development, Inc.CompletedHealthy Volunteers | Pharmacokinetics of ASP015K | Food EffectUnited States
-
Astellas Pharma China, Inc.CompletedPharmacokinetics of Mirabegron | Food Effect | Healthy Chinese SubjectsChina
-
Astellas Pharma Global Development, Inc.CompletedHealthy Subjects | Pharmacokinetics of ASP4058 | Food Effect of ASP4058United States
Clinical Trials on E7386
-
Eisai LimitedSuspended
-
Eisai Inc.RecruitingAdvanced NeoplasmsUnited States, United Kingdom
-
Eisai LimitedCompleted
-
Eisai Co., Ltd.Active, not recruitingColorectal Neoplasms | Gastrointestinal Tumors | Solid NeoplasmsJapan
-
Medicines for Malaria VentureMahidol UniversityCompletedMalaria, Falciparum | Malaria, Vivax
-
Eisai Inc.RecruitingNeoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Colorectal Neoplasms | Endometrial NeoplasmsUnited States, Taiwan, France, Japan, Korea, Republic of
-
Eisai Inc.Merck Sharp & Dohme LLCRecruitingMelanoma | Carcinoma, Hepatocellular | Colorectal NeoplasmsSpain, United States, United Kingdom, Japan, France